Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05)

医学 曲妥珠单抗 曲妥珠单抗 内科学 肿瘤科 乳腺癌 抗体-药物偶联物 耐火材料(行星科学) 化疗 新辅助治疗 HER2/东北 癌症 抗体 免疫学 单克隆抗体 物理 天体生物学
作者
Michael Untch,CE Geyer,Aleix Prat,Priya Rastogi,Naoki Niikura,Elodie Mathias,LA McLean,Y Wang,Sibylle Loibl
出处
期刊:Senologie [Georg Thieme Verlag]
被引量:1
标识
DOI:10.1055/s-0041-1730235
摘要

Background Patients with residual invasive disease after NAT are at greater risk for disease recurrence or death than those with a pathological complete response. The antibody-drug conjugate (ADC) T-DM1 was recently approved as postneoadjuvant treatment for patients with residual invasive disease (in breast and/or axillary nodes) after NAT and anti-HER2-treatment. T-DXd is a potent HER2-targeted ADC that was recently approved following phase 2 evidence (Modi NEJM 2020) for the treatment of patients with HER2-positive, unresectable/metastatic BC with ≥2 prior anti-HER2─based regimens (US) or prior chemotherapy and being refractory to or intolerant of standard treatments (Japan). Methods DESTINY-Breast05 is a multicenter, open-label, randomized, phase 3 trial comparing efficacy and safety of T-DXd with T-DM1 in patients with HER2-positive (IHC 3+ or ISH+, centrally confirmed on pretreatment biopsy), invasive BC with residual invasive disease (breast and/or axillary lymph nodes) at presentation after NAT. Patients are eligible with either inoperable (cT4, N0-3, M0 or cT1-3, N2-3, M0) or operable BC (cT1-3, N0-1, M0) with axillary node-positive disease after NAT and anti-HER2-treatment. Approximately 1600 patients from 400 sites globally will be randomized (1:1) to T-DXd (5.4mg/kg) or T-DM1 (3.6mg/kg) intravenously once every 3 weeks for 14 cycles, stratified by operative status, hormone-receptor status, pathological nodal status, and anti-HER2-therapy. Primary endpoint is invasive disease-free survival, key secondary endpoint is disease-free survival. Other secondary endpoints are overall survival, distant recurrence-free interval, brain metastasis-free interval, safety. Pharmacokinetics of T-DXd, biomarkers, and health-related quality of life will be evaluated. Study start in Germany is planned for April 2021. Publication History Article published online: 01 June 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
null的应助被飘逸雨竹采纳,获得10
刚刚
1秒前
weifengzhong发布了新的文献求助10
1秒前
美团小骑手完成签到,获得积分10
1秒前
63发布了新的文献求助10
2秒前
852的应助被凌晨采纳,获得10
3秒前
3秒前
6666的应助被无私藏鸟采纳,获得30
4秒前
科研通AI6.2的应助被Lin采纳,获得10
4秒前
5秒前
开心快乐大王完成签到 ,获得积分10
5秒前
笨笨豌豆完成签到 ,获得积分10
7秒前
舒服的牛排发布了新的文献求助200
8秒前
8秒前
香蕉觅云的应助被哟邮票采纳,获得10
8秒前
9秒前
9秒前
9秒前
aaaa的应助被搞科研的肥宅吴采纳,获得30
9秒前
9秒前
123发布了新的文献求助10
9秒前
mvver完成签到,获得积分20
10秒前
科目三的应助被samxie采纳,获得10
10秒前
Jxh关注了科研通微信公众号
11秒前
11秒前
lkk完成签到,获得积分10
12秒前
12秒前
13秒前
14秒前
爆米花的应助被yzy采纳,获得10
14秒前
14秒前
哒哒哒哒哒哒完成签到,获得积分20
15秒前
15秒前
15秒前
Ava的应助被zhangxu采纳,获得10
16秒前
17秒前
17秒前
17秒前
18秒前
yy完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211